GlySure Secures CE Mark and Launches World’s First Continuous Intravascular...
ABINGDON, England GlySure Limited today announced that it has secured the CE Mark for the world’s first and only Continuous Intravascular Glucose Monitoring System (CIGMS). The initial use of the...
View ArticleGenesisCare Acquires Cancer Partners UK – Cancer Patients to Benefit from...
SYDNEY GenesisCare, Australia’s largest provider of radiotherapy services (GenesisCare), today announced the acquisition of the United Kingdom’s leading provider of private cancer services, Cancer...
View ArticleNuGEN Scientists Screen 400+ Genes for Fusion Events in Single Assay; Detect...
SAN CARLOS, Calif. Scientists at NuGEN Technologies, Inc. have simultaneously surveyed RNA of more than 400 targeted genes in a single assay, using next generation sequencing (NGS) to detect fusions...
View ArticleProvectus Biopharmaceuticals Signs Letter of Intent with Boehringer Ingelheim...
KNOXVILLE, Tenn. Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”),...
View ArticleLENSAR Expands Presence in India; Sharp Sight Centres Choose the LENSAR Laser...
ORLANDO, Fla. & DELHI, India LENSAR, Inc., a global leader in next generation femtosecond laser technology for refractive cataract surgery, today announced the Sharp Sight Centres now offer the...
View ArticleIndia’s Refractive Surgery Society Awards Special Gold Medal to LENSAR CEO...
ORLANDO, Fla. & CHENNAI, India The Intraocular Implant and Refractive Society of India (IIRSI) awarded a Special Gold Medal to Nicholas T. Curtis, CEO of LENSAR, Inc., a global leader in next...
View ArticleProvectus Biopharmaceuticals’ Phase 1 PV-10 Data on Liver Cancer Presented at...
KNOXVILLE, Tenn. Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”),...
View ArticleSpok and Xovic Partner to Improve Critical Communications for Thailand Hospitals
PERTH, Australia Spok, Inc. today announced that it has partnered with Thailand-based medical distributor Xovic to enable healthcare organisations to improve efficiency and safety with better staff...
View ArticleInvestigation Finds Asbestos Fibers in Crayons and Toys from China
WASHINGTON The Asbestos Disease Awareness Organization (ADAO), which combines education, advocacy, and community to prevent exposure and ensure justice for asbestos victims, is outraged by the...
View ArticleCardiovascular Systems Completes Coast Study Enrollment
ST. PAUL, Minn. Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), announced that it has completed enrollment for its Coronary Orbital Atherectomy System Trial (COAST) study. Taking place in both...
View ArticleTakeda Submits New Drug Application for Ixazomib for Patients with...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that a New Drug Application (NDA) has been submitted to the United States (U.S.) Food and Drug...
View ArticleMulti-Site Study Validates End-to-End RNA-Seq Sample Prep Workflow for Human...
SAN CARLOS, Calif. & PISCATAWAY, N.J. A multi-site study has clinically validated an end-to-end workflow for the collection, storage, transport and preparation of human whole blood samples for...
View ArticleCANbridge Acquires License for Apogenix’s APG101 Onco-Immunotherapy in...
BEIJING CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has entered into an exclusive license agreement with...
View ArticleProNova凭借荷兰交易拓展欧洲业务
田纳西州马里维尔 (美国商业资讯)–阿姆斯特丹的一家新设质子疗法中心已选中ProNova Solutions作为设备供应商,该中心计划在2018年开始治疗患者。 阿姆斯特丹质子疗法中心(APTC)是学术医疗中心、阿姆斯特丹自由大学医疗中心和荷兰癌症研究所的合作项目,该中心宣布已选用ProNova为该新设施提供治疗系统,该设施每年能够为约600例患者提供质子疗法。 ProNova...
View ArticleProvectus Biopharmaceuticals, Sinopharm-China State Institute of...
KNOXVILLE, Tenn. Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”),...
View Article武田递交ixazomib用于复发/难治多发性骨髓瘤患者的新药申请
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE: 4502)今天宣布,已向美国(U.S.)食品药品管理局(FDA)递交ixazomib的新药申请(NDA),ixazomib是口服蛋白酶体抑制剂类研究药物,用于治疗复发和/或难治多发性骨髓瘤。...
View Article武田薬品が再発性/難治性の多発性骨髄腫患者の治療薬ixazomibで新薬承認申請
米マサチューセッツ州ケンブリッジ & 大阪 (ビジネスワイヤ)– 武田薬品工業株式会社(TSE: 4502)は本日、ixazomibの新薬承認申請(NDA)を米食品医薬品局(FDA)に行ったと発表しました。ixazomibは経口治験薬としてのプロテアソーム阻害薬で再発性もしくは難治性または両方の多発性骨髄腫患者の治療を目的としています。...
View Article患者安全运动基金会与查普曼大学药学院共同召开年中规划会议
加州尔湾 (美国商业资讯)–患者安全运动基金会(Patient Safety Movement Foundation)定于2015年7月29日与查普曼大学药学院(Chapman University School of Pharmacy)共同召开两家单位的年中规划会议,会议地点设在查普曼大学位于加州奥兰治的主校区。...
View ArticleGenoLogics Releases Clarity LIMS X as Part of Illumina SeqLab
REDWOOD CITY, Calif. GenoLogics today announced the availability of Clarity LIMS X, an edition of its industry-leading laboratory informatics platform. Optimized for use with Illumina® SeqLab, the X...
View ArticleSaki America Relocates Office to Fremont, California
SAN JOSE, Calif. Saki Corporation, an innovator in the field of automated optical inspection equipment, announces the relocation of the Saki America office to Fremont, California. The new office,...
View Article